Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Low for a penny stock!
go NFRM
Thanks!!! NFRM has updated the website last month, check it out
http://www.nationalpharmacorp.com/
Now your talking lol The $NFRM board will never be the same!!
Good Job, nah, Great Job on the NFRM ibox
I think so HH penny $NFRM is ready for a huge bounce IMO!!!
I don't mind at all, will this be a disco NFRM party?
Looks good here!
100mA/S oK!!!
Yes weeeeeeeeeee hahahaha..
Good job langlui :P
Go NFRM!
NFRM News March 11th:
National Pharmaceuticals' Lead Therapeutic Drug, GLB333 Receives Financial Grant
Friday March 11, 2011, 9:00 am EST
MIAMI, FLORIDA--(Marketwire - 03/11/11) - National Pharmaceuticals Corp. (PINK SHEETS:NFRM - News) or the "Company" is pleased to announce that its lead therapeutic drug, GLB333 was awarded a grant from Canada's National Research Council. The grant will be used toward development methods for large scale manufacturing of the drug. The grant which is awarded to Globe Laboratories, the licensor of the technology is for $30,000 for this year and can be increased significantly upon completion of preliminary feasibility studies. National has signed a letter of intent with Globe labs to license GLB333, a drug believed to be effective in vascular regeneration, organ transplant and wound healing. The product may have other therapeutic benefits, including pain management due to muscle injury and trauma.
"We are pleased with this Government financial grant for our product which further endorses the need for its rapid development and commercialization," said Elaine Affleck, President of National Pharmaceuticals Corp.
NFRM News March 16th:
National Pharmaceuticals Corp. Appoints Chief Scientific Advisor
Wednesday March 16, 2011, 9:00 am EDT
MIAMI, FLORIDA--(Marketwire - 03/16/11) - National Pharmaceuticals Corp. (PINK SHEETS:NFRM - News) or the "Company" announced today that it has appointed Dr. Gary Yalloway as its Chief Scientific Advisor.
Dr. Yalloway is a well known leading researcher on cytokines and growth factors. He has designed the production of GLB333 through recombinant technologies at Globe Laboratories where he currently is the Chief Operating Officer and Head of all Technologies. He brings to NFRM over 14 years of multidisciplinary research experience and skills in protein engineering and the structural functional relationships of proteins of medical and industrial interest.
Dr. Yalloway earned his Ph.D. from University College, Dublin, Ireland and was a post doctoral fellow at the Institute for Biophysical Chemistry, Frankfurt, Germany and the University of British Columbia, Vancouver, Canada. Dr Yalloway was also a postdoctoral research associate at Simon Fraser University where he was lab manager and a team leader responsible for the project management of junior scientists. He served as senior research officer at Chemokine Therapeutics.
"Dr. Yalloway has outstanding skills and vast experience in biopharmaceutical drugs development.", said Elaine Affleck, President of National Pharmaceuticals Corp. "We are pleased to have Dr. Yalloway lead our scientific team and supervise the development of GLB333", Added Ms. Affleck.
Oh Ye$$$, You better wear your sunglasses tomorrow if you plan on watching NFRM run Up ;)
NFRM News March 18th:
National Pharmaceuticals Corp. in Association With Globe Labs to Enter Into Discussion on Clinical Trials Protocols for GLB333
Friday March 18, 2011, 8:05 am EDT
MIAMI, FLORIDA--(Marketwire - 03/18/11) - National Pharmaceuticals Corp. (PINK SHEETS:NFRM - News) or the "Company" announced today that in conjunction with Globe Laboratories have identified a contract research organization (CRO) from Europe to develop protocols for clinical trials of GLB333. Parties have decided that the Clinical Investigations group from Vienna, Austria would be most suitable for conducting the Phase I clinical trials. The trials which would be the first for GLB333 shall focus on the ability of the drug to speed up wound healing in diabetes patients suffering from chronic wound and tissue efflux.
"We are pleased to have this critical step initiated to identify and potentially engage a strong and experienced CRO group to advise us and conduct the necessary work with our drug for proof of efficacy and performance", said Elaine Affleck, President of National Pharmaceuticals Corp.
NFRM News March 22nd:
National Pharmaceuticals Completes Licensing of GLB333 From Globe Labs
Tuesday March 22, 2011, 4:00 pm EDT
MIAMI, FLORIDA--(Marketwire - 03/22/11) - National Pharmaceuticals Corp. (PINK SHEETS:NFRM - News) or the "Company" announced today that it has completed the licensing of GLB333 from Globe Laboratories. NFRM obtained the worldwide exclusive license to the use and marketing of a cytokine that is shown to have profound effects on the management of pain due to trauma, wound, and accidents, as well as autoimmune conditions. The product under the internal name GLB333 has a different mechanism of action to current pain killers or analgesics. It helps to rebuild the damage tissues, reduces inflammatory conditions and help to regenerate good and healthy muscle and soft tissues. Globe Laboratories has worked on the biology and use of the product for several years and has spent considerable resources on its development. The license is for twenty years and carries standard terms and conditions used by other companies in this sector.
"We are pleased to obtain the exclusive license to the technology on worldwide basis for GLB333. The product that has considerable data already, will be ready for clinical trials Phase I/II in near future," said Elaine Affleck, President of National Pharmaceuticals Corp.
NFRM News April 6th
National Pharmaceuticals Lead Therapeutic Drug, GLB333 Application in Lupus
Wednesday April 6, 2011, 12:30 am EDT
MIAMI, FLORIDA--(Marketwire - 04/06/11) - National Pharmaceuticals Corp. (PINK SHEETS:NFRM - News) or the "Company" is pleased to announce that its partner, Globe Laboratories concluded that GLB333, the Company's Lead Therapeutic drug may have effect in the treatment of Lupus. Lupus complications are caused by over expression of certain cytokine (interleukins) according to several scientific reports. The drug GLB333 is an inhibitor of a cytokine that is involved in lupus. Globe Labs has indicated that the drug should be beneficial to treat lupus, due to its inhibitory action on cytokine or interleukin function. There are approximately 1,400,000 lupus patients in the United States according to the Scripps Magazine report (http://www.scripps.edu/philanthropy/lupus.html?origin=ggdislupus). To date there is no effective treatment availed for lupus sufferers. While the actual cause of the disease is not known, but the presence of cytokines or interleukins are well documented.
About lupus
Lupus, an autoimmune disease, happens when the immune system attacks its tissues, causing inflammation, swelling, pain, and damage. Lupus symptoms vary, and early lupus symptoms include fatigue, joint pain, fever, and a lupus rash, especially after being in the sun. Familiarize yourself with pictures of the lupus rash. Doctors diagnose lupus by symptoms and blood tests. Lupus is not contagious but has a hereditary component. For information, please visit the lupus Foundation of America (http://www.lupus.org/newsite/index.html).
Let me guess....hmmmmmmm.....did you make NFRM IBox?
NFRM Products
Our first product is a cytokine inhibitor known as GLB333. This product once used can prevent the action of those molecules and mediators that are involved in the worsening of tissue injury and causing pain. GLB333 is a biopharmaceutical drug in the mid stage of development. The product is believed to have powerful effect on preventing the action of those cytokines that are release around the damaged tissue and lead to sever inflammation and pain. It is our belief this is only breakthrough in the management of systemic tissue injury and treatment of pain.
NFRM About Us -
We are a biotechnology company with focus on tissue and muscle injury. Injuries to muscle such as back pain or ligaments and vascular injuries such as sclerosis are often permanent and carry significant socioeconomic consequences. About 10 million people in the United States suffer from back muscle injuries that have become a chronic back pain. Another 2-3 million suffer from sport related injuries, ligaments stretched, spasm etc. These conditions carries a life time pain, that can not be resolved by normal and usual pain killers. Pain and suffering from these injuries are due to the constant release of chemical mediators, known as cytokines. We have discovered molecules, known as growth factors that prevent the effect of these cytokines and associated pain by preventing further damage to the tissue and rebuilding the damaged tissues.
Guess who made the iBox for NFRM
Looks to me from the chart $NFRM has a long way to go on the upside!!!
I really don't think NFRM Buzz Cloud will be able to contain itself tonight ;)
Oh Ye$$$ you will Love NFRM More ;)
Indeed with $NFRM's float we could see a very nice bounce here!!
You too Teaks, See you on the flip side, sweet dreams of NFRM $$ ;)
have a great night all, looking forward to trading NFRM tomorrow!
with plenty of room to run my friend!
$NFRM
Products
Our first product is a cytokine inhibitor known as GLB333. This product once used can prevent the action of those molecules and mediators that are involved in the worsening of tissue injury and causing pain. GLB333 is a biopharmaceutical drug in the mid stage of development. The product is believed to have powerful effect on preventing the action of those cytokines that are release around the damaged tissue and lead to sever inflammation and pain. It is our belief this is only breakthrough in the management of systemic tissue injury and treatment of pain.
NFRM mfi is at 78 and the rsi is rising at 38 nice indicators
Indeed I will love $NFRM more!!
$$NFRM:NFRM just announced some major news 2 weeks ago that the company’s lead therapeutic drug GLB333 may have effect in the treatment of Lupus. There are around 1,400,000 lupus patient just in the United States today.
$$NFRM..wait till tomorrow..cloud will be exploding..
Hey, NFRM is all over the Buzz Clouds ;)
No kiddin', it would be more fun to see NFRM Explode tomorrow ;)
$$NFRM..I can tell ya'll bout back pain..on the strongest pain killer known to man...luv this company more already
News and some upward momo would absolutely be the makings of a huge bounce for NFRM
looking forward to it my friend! NFRM looks like it could be lots of fun!
$$NFRM: and pharma companies, I luv the news they can have..and would be a real catalyst the way this is set up..news would be a rocker
Good to see us make some $$$$$$$$$$$$$$$$$ tomoro lol
You're going to love it more when NFRM takes off tomorrow morning ;)
im one of those 10 million with back pain... maybe i can find some relief here, and in my portfolio while im at it! go NFRM!
$NFRM
About Us
We are a biotechnology company with focus on tissue and muscle injury. Injuries to muscle such as back pain or ligaments and vascular injuries such as sclerosis are often permanent and carry significant socioeconomic consequences. About 10 million people in the United States suffer from back muscle injuries that have become a chronic back pain. Another 2-3 million suffer from sport related injuries, ligaments stretched, spasm etc. These conditions carries a life time pain, that can not be resolved by normal and usual pain killers. Pain and suffering from these injuries are due to the constant release of chemical mediators, known as cytokines. We have discovered molecules, known as growth factors that prevent the effect of these cytokines and associated pain by preventing further damage to the tissue and rebuilding the damaged tissues.
I agree, quite bottomed right now, ripe for a huge move up!
I love it when you talk that way!!
NFRM:I am seeing lot's of blue skies on that chart!!
if NFRM breaks .10 it could really bust wide open!
great support at .03 last time we saw momo on 4/5 she ran to .09 on 4/6 we could see a repeat performance for $NFRM
yes, it can be VERY fun ;) the MA50 is at .10 that would be a nice move from here!
whats good my friend?
Bouncing can be fun ;)
How high can NFRM go?
Followers
|
51
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
4167
|
Created
|
09/16/10
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |